Skip to main content
SpringerLink
Log in

Update für den Hausarzt

Typ-2-Diabetes: Was ist neu? Was ist überholt? Was bleibt?

Type 2 diabetes: What’s new? What is outdated? What stays?

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

In den letzten Jahren gab es beim Typ-2-Diabetes Innovationen, die die bisherigen Behandlungsalgorithmen grundlegend verändern und für Patienten neue Optionen und alltagsrelevante Vorteile bieten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015:373:2117–28.

    Article  CAS  Google Scholar 

  2. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016:375:311–22.

    Article  CAS  Google Scholar 

  3. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016:375:323–34.

    Article  CAS  Google Scholar 

  4. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019:380:347–35

    Article  CAS  Google Scholar 

  5. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018:61:2108–2117

    Article  CAS  Google Scholar 

  6. Davies MJ, D’Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018:12:2669–2701.

    Article  Google Scholar 

  7. Gehr B, Biester T. Kontinuierliche Glukosemessung — Auf dem Weg zum Standard in der Diabetestherapie. Der Diabetologe 2018:6

  8. Ahlqvist E, Storm P, Käräjämäki A et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018:6:361–69.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max-Josefs-Platz 21, D-83022, Rosenheim, Deutschland

    Michael Hummel (Diabetologische Schwerpunktpraxis Rosenheim)

Authors
  1. Michael Hummel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Hummel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hummel, M. Typ-2-Diabetes: Was ist neu? Was ist überholt? Was bleibt?. MMW - Fortschritte der Medizin 161, 45–49 (2019). https://doi.org/10.1007/s15006-019-0511-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-0511-y

Keywords

Search

Navigation